Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: An open-label prospective study

Clinical Drug Investigation

Volumn 31, Issue 5, 2011, Pages 299-307

  Kasztalska, Karolina ^a   Ciebiada, MacIej ^a   Cebula Obrzut, Barbara ^a   Górski, Paweł ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Immune globulin; Immunodeficiency disorders; therapeutic use; treatment

Indexed keywords

CD19 ANTIBODY; CD4 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SUBSTITUTION THERAPY;

ADOLESCENT; ADULT; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; YOUNG ADULT;

EID: 79953812343     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586710-000000000-00000     Document Type: Article

References (31)

1. Sewell WAC, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107: 387-93 (Pubitemid 36693642)
2. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33 (Pubitemid 351600384)
3. Orange JS, Hossny EM, Weiler CR, et al., Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol2006; 117 (4 Suppl.): 525-53
4. Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulins in autoimmune and inflammatory diseases. Neurol Sci 2003; (4 Suppl.): 217-21
5. Wood P, Stanworth S, Burton J, et al., UK Primary Immunodeficiency Network. Recognition, clinical diag-nosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149 (3): 410-23 (Pubitemid 47256150)
6. Report of an IUIS Scientific Committee. Primary immunodeficiency diseases. Clin Exp Immunol 1999; 118: 1-28
7. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359 (3): 307-9
8. Siberil S, Elluru S, Graff-Dubois S. Intravenous immunoglobulins in autoimmune and inflammatory diseases. Ann NY Acad Sci 2007; 1110: 497-506 (Pubitemid 350043039)
9. Samuelsson A, Towers TL, Revetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc re-ceptor. Science 2001; 291 (5503): 484-6 (Pubitemid 32097072)
10. Seite JF, Shoenfeld Y, Youinou P, et al. What is the content of the magic draft IVIg? Autoimmun Rev 2008 Jun; 7 (6): 435-9
11. Sewell WAC, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immuno-globulin. Clin Exp Immunol 1999; 116 (3): 509-15 (Pubitemid 29258104)
12. Bayry J, Fournier EM, Maddur MS. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immuno-deficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011 Feb; 36 (1): 9-15
13. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007; 3 (5): 262-72 (Pubitemid 46711473)
14. European Society for Immunodeficiencies (ESID). Diagnostic criteria for PID [online]. Available from URL: http://www.esid.org/workingparty.php?party= 3&sub=2&id =73#Q5 [Accessed 2010 Mar 1]
15. Park MA, Li JT, Hagan JB, et al. Common variable immunodeficiency: a new look at an old disease. Lancet 2008; 372 (9637): 489-502
16. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29 (12): 608-15
17. Bayry J, Lacroix-Desmazes S, Hermine O, et al. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 2005; 118 (12): 1439-40 (Pubitemid 41832358)
18. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 2004; 101 (39): 14210-5 (Pubitemid 39305055)
19. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol2007; 179 (8): 5571-5
20. Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203 (7): 1701-11 (Pubitemid 44036276)
21. Melo KM, Carvalho KI, Bruno FR, et al. A decreased frequency of regulatory T cells in patients with common variable immunodeficiency. PLoS One 2009; 4 (7): e6269
22. Horn J, Manguiat A, Berglund LJ, et al. Decrease in phenotypic regulatory T cells in subsets of patients with com-mon variable immunodeficiency. Clin Exp Immunol 2009; 156 (3): 446-54
23. Le Pottier L, Sapir T, Bendaoud B, et al. Intravenous immunoglobulin and cytokines. Ann NY Acad Sci 2007; 1110: 426-32
24. Bayry J, Hermine O, Webster DA, et al. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med 2005; 11 (8): 370-6 (Pubitemid 41080578)
25. Salzer U, Grimbacher B. Common variable immunodeficiency: the power of co-stimulation. Semin Immunol 2006; 18: 337-46 (Pubitemid 44511883)
26. Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bi-directional interaction between dendritic cells and natural killer cells. Blood 2007; 110: 3253-62 (Pubitemid 350106318)
27. Rankin CT, Veri MC, Gorlatov S, et al. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for mono-clonal antibody therapy ofB-cell lymphoma. Blood 2006; 108 (7): 2384-91 (Pubitemid 44497523)
28. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25 (1): 1-18 (Pubitemid 40386174)
29. Brownlie RJ, Lawlor KE, Niederer HA, et al. Distinct cell-specific control of autoimmunity and infection by Fc gamma RIIb. J Exp Med 2008; 205 (4): 883-95 (Pubitemid 351549885)
30. Ghio M, Contini P, Setti M, et al. sHLA-I contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin in-fusion. J Clin Immunol 2010; 30 (3): 384-92
31. Alder LB, Morgan LA, Spickett GP. Contribution of sta-bilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell prolifera-tion in vitro. Scand J Immunol 1996; 44 (6): 585-91 (Pubitemid 26400372)